Professor Glyn Taylor
BSc, PhD, MIoD
Honorary Professor
Overview
Qualifications
PhD in Pharmacokinetics from Manchester University (1981)
BSc (Pharmacy) from Aston University (1976)
Research Interests
Pulmonary Drug Delivery
Pharmaceutical Scintigraphy
Environmental Improvements for Medicinal Inhalers
Variability in Pharmacokinetics
A member of the School's Drug Delivery & Microbiology Research Discipline
Biography
I graduated with a BSc in Pharmacy from Aston University in 1976 and a PhD in Pharmacokinetics from Manchester University in 1981. I joined the faculty of the Welsh School of Pharmacy in Cardiff during 1980 and was subsequently appointed as a Research Fellow in Clinical Pharmacology at Stanford University (1982-1983) and as a Visiting Assistant Professor at the University of California, San Francisco, School of Pharmacy (1989-1990).
In 1992, I co-founded Cardiff Scintigraphics, a Cardiff University spin-out company focussed on the clinical and in vitro evaluation of pharmaceuticals and drug delivery systems using techniques including gamma scintigraphy. In addition to a joint venture with Europe’s longest established Clinical Research Organisation Simbec, the spin-out company has also focused on novel (non-CFC) formulation strategies for inhalation drug delivery. He has delivered many lectures to academic, industrial and commercial organisations in the UK and in the US and has authored or co-authored more than 150 research articles, in the areas of pharmacokinetics, biopharmaceutics and gamma scintigraphy. To date, 20 graduate students have been awarded PhD degrees under my supervision.
Professional memberships
I am a reviewer for BBSRC, Wellcome Foundation and a member of the Bioequivalence Ad Hoc Group of the MHRA.
Publications
2016
- Paul, G., Somers, G. and Taylor, G. 2016. Implications for room lighting and the duration of acclimation protocols on the dosimetry of inhaled drugs in rats. Respiratory Drug Delivery 2, pp. 327-332.
2013
- Aljayyoussi, G. et al. 2013. Selectivity in the impact of P-glycoprotein upon pulmonary absorption of airway-dosed substrates: A study in ex vivo lung models using chemical inhibition and genetic knockout. Journal of Pharmaceutical Sciences 102(9), pp. 3382-3394. (10.1002/jps.23587)
2012
- Newman, S. et al. 2012. Standardization of Techniques for Using Planar (2D) Imaging for Aerosol Deposition Assessment of Orally Inhaled Products. Journal of Aerosol Medicine and Pulmonary Drug Delivery 25(S1), pp. S10-S28. (10.1089/jamp.2012.1Su4)
- Devadason, S. G. et al. 2012. Validation of Radiolabeling of Drug Formulations for Aerosol Deposition Assessment of Orally Inhaled Products. Journal of Aerosol Medicine and Pulmonary Drug Delivery 25(S1), pp. S6-S9. (10.1089/jamp.2012.1Su3)
2011
- Kellerman, D. et al. 2011. Lack of drug interaction between the migraine drug MAP0004 (orally inhaled dihydroergotamine) and a CYP3A4 inhibitor in humans. Cephalalgia 32(2), pp. 150-158. (10.1177/0333102411432299)
2010
- Bains, B. K., Birchall, J. C., Toon, R. and Taylor, G. 2010. In vitro reporter gene transfection via plasm ID DNA delivered by metered dose inhaler. Journal of Pharmaceutical Sciences 99(7), pp. 3089-3099. (10.1002/jps.22085)
- Nikander, K., Prince, I., Coughlin, S., Warren, S. J. and Taylor, G. 2010. Mode of breathing- tidal or slow and deep-through the I-neb Adaptive Aerosol Delivery (AAD) System affects lung deposition of Tc-99m-DTPA. Journal of Aerosol Medicine and Pulmonary Drug Delivery 23(S1), pp. S37-S43. (10.1089/jamp.2009.0786)
- Hampson, F. C., Jolliffe, I. G., Bakhtyari, A., Taylor, G., Sykes, J., Johnstone, L. M. and Dettmar, P. W. 2010. Alginate-antacid combinations: raft formation and gastric retention studies. Drug Development and Industrial Pharmacy 36(5), pp. 614-623. (10.3109/03639040903388290)
2009
- Weers, J., Metzheiser, B., Taylor, G., Warren, S. J., Meers, P. and Perkins, W. R. 2009. A gamma scintigraphy study to investigate lung deposition and clearance of inhaled amikacin-loaded liposomes in healthy male volunteers. Journal of Aerosol Medicine and Pulmonary Drug Delivery 22(2), pp. 131-138. (10.1089/jamp.2008.0693)
2008
- Shrewsbury, S. B., Cook, R. O., Taylor, G., Edwards, C. and Ramadan, N. M. 2008. Safety and pharmacokinetics of dihydroergotamine mesylate administered via a novel (Tempo™) inhaler. Headache 48(3), pp. 355-367.
2007
- Bains, B. K., Taylor, G., Toon, R. and Birchall, J. C. 2007. Novel nanoparticles for pulmonary gene delivery [Abstract]. Pharmacy and Pharmacology 59(S1), pp. A31-A32. (10.1211/002235707781850140)
- Buggins, T. R., Dickinson, P. A. and Taylor, G. 2007. The effects of pharmaceutical excipients on drug disposition. Advanced Drug Delivery Reviews 59(15), pp. 1482-1503. (10.1016/j.addr.2007.08.017)
- Shrewsbury, S. B., Cook, R., Taylor, G., Edwards, C. and Ramadan, N. 2007. Clinical safety of inhaled dihydroergotamine mesylate via a novel system (Tempo (TM) inhaler). Headache 47(5), pp. 753-754.
- Shrewsbury, S. B., Cook, R., Taylor, G., Edwards, C. and Ramadan, N. 2007. Comparative clinical pharmacokinetics of parent drug and metabolites following inhaled dosing with dihydroergotamine mesylate via a novel system (Tempo (TM) inhaler). Headache 47(5), pp. 754-754.
2005
- Li, H., Jeans, C., Birchall, J. C. and Taylor, G. 2005. Nanoparticles for pulmonary drug delivery [Abstract]. Journal of Pharmacy and Pharmacology 57(S1), pp. S20. (10.1211/002235705778248569)
2004
- Boyd, B. et al. 2004. Effect of Gender and Device Mouthpiece Shape on Bolus Insulin Aerosol Delivery Using the AERxPulmonary Delivery System. Pharmaceutical Research 21(10), pp. 1776-1782. (10.1023/B:PHAM.0000045228.32419.ba)
2002
- Warren, S., Taylor, G., Smith, J., Buck, H. and Parry-Billings, M. 2002. Gamma Scintigraphic Evaluation of a Novel Budesonide Dry Powder Inhaler Using a Validated Radiolabeling Technique. Journal of Aerosol Medicine 15(1), pp. 15-25. (10.1089/08942680252908548)
1995
- Colthorpe, P., Fair, S. J., Smith, I. J., Wyatt, D. and Taylor, G. 1995. The Influence of Regional Deposition on the Pharmacokinetics of Pulmonary-Delivered Human Growth Hormone in Rabbits. Pharmaceutical Research 12(3), pp. 356-359. (10.1023/A:1016292232513)
- Farr, S. J., Rowe, A. M., Rubsamen, R. and Taylor, G. 1995. Aerosol deposition in the human lung following administration from a microprocessor controlled pressurised metered dose inhaler. Thorax 50(6), pp. 639-644. (10.1136/thx.50.6.639)
Research Interest
My main research aim is to elucidate factors which influence variability in pharmacokinetics. This encompasses both pre-clinical investigations of formulation excipients on drug delivery and absorption and clinical investigations using gamma scintigraphy to investigate patient and device variables on the optimisation of drug deposition and delivery to appropriate absorption sites, particularly the lung.